Skip to main content
xMedica

NCT07293247ClinicalTrials.gov

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining…

Phase 2164 participants sought125 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-12-19; recorded start 2026-10-14
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 97 other studies in this databaseCounted from the lead sponsor named in the record (Alliance for Clinical Trials in Oncology)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: other.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding0/20

    Open-label

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 33 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study: 164 participants (target), run at 125 sites.

How this score is built
  • Enrolment21/40

    164 participants (target)

  • Site count18/25

    33 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 69 months

  • Sponsor scale7/10

    Alliance for Clinical Trials in Oncology has led 96 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node cancer after surgery. Radiation therapy uses high-energy X-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding I²-PORT radiation therapy to standard therapy may be more effective than standard therapy alone in reducing the risk of cancer returning in those who have undergone surgery for NSCLC.

PRIMARY OBJECTIVES: I. To assess whether intensity-modulated post-operative radiation therapy (I²-PORT) improves disease-free survival (DFS) of patients with R0 resected ypN2 NSCLC compared to standard of care (SOC). II. To assess whether I²-PORT does not unacceptably increase (by ≥ 6.5 percentage points) the rate of severe (grade ≥ 3 per Common Terminology Criteria for Adverse Events \[CTCAE\] version \[v\] 5) late cardiopulmonary toxicity compared to SOC. SECONDARY OBJECTIVES: I. 5-year DFS, 2- and 5-year overall survival (OS). II. Local versus (vs.) regional control, rate of distant metastases. III. Acute and late adverse events (AE) rates of specific cardiac, pulmonary, and other toxicities, per CTCAE version 5.0. IV. Rates of non-mild, moderate, or severe-very severe symptoms per Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE), particularly terms related to cardiopulmonary toxicities, e.g., pain, shortness of breath, cough, wheezing, and heart palpitations. V. Subset analyses by single vs. multi-station N2 and by adequacy of surgical nodal evaluation. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI), fludeoxyglucose-positron emission tomography (FDG-PET), and blood sample collection throughout the study. ARM II: Patients undergo I²-PORT once daily (QD) Monday through Friday over 15-25 fractions over 5-6 weeks, starting 4-12 weeks after surgery. Radiation simulation should be performed within 21 days of starting I²-PORT. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on the study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for 3 years.

Conditions

  • Lung Non-Small Cell Carcinoma

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

* Histopathologic diagnosis of NSCLC, may have mixed or multiple histologies but no small cell component * No known EGFR mutation or ALK rearrangement * No metastatic disease (M0) per most recent PET/CT and head CT/MRI imaging * No disease progression per CT chest (including upper abdomen as per standard practice) with intravenous (IV) contrast (unless IV contrast is contraindicated) or FDG-PET performed post-neoadjuvant therapy ≤ 90 days prior to registration, either before or after surgery * No metastatic disease (M0) per head CT/MRI imaging * Prior treatment with 2-4 cycles of neoadjuvant systemic therapy with any guideline (National Comprehensive Cancer Network \[NCCN\]) concordant regimen * Lobectomy or greater oncologic surgical resection within 8 weeks prior to registration * Complete (R0) resection showing ypN2 disease * No prior radiotherapy to the lungs or mediastinum * No treatment with a VEGF inhibitor ≤ 90 days prior to registration or plan to treat with adjuvant systemic therapy including a VEGF inhibitor * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 * Platelet count ≥ 50,000/mm\^3 * Calculated (Calc.) creatinine clearance ≥ 30 mL/min * Total bilirubin ≤ 3 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 5 x upper limit of normal (ULN) * Not pregnant, because this study involves radiation therapy, which has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done ≤ 7 days prior to registration is required * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Cardiac function: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * No idiopathic pulmonary fibrosis requiring anti-fibrotic medication: Patients with idiopathic pulmonary fibrosis or inflammatory/interstitial lung disease compromising pulmonary function or requiring ongoing treatment with nintedanib, pirfenidone, or other anti-fibrotic drug are excluded * HIV-infected patients on effective anti-retroviral therapy with an undetectable viral load within 6 months are eligible for this trial

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 2
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingNONE (0)
Enrolment164 participants sought

Sponsor and collaborators

  • Alliance for Clinical Trials in Oncology Sponsor
  • National Cancer Institute (NCI) Collaborators

Arms and interventions

  • Arm I (SOC chemotherapy/immunotherapy)ACTIVE_COMPARATOR

    Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.

  • Arm II (I²-PORT, SOC chemotherapy/immunotherapy)EXPERIMENTAL

    Patients undergo I²-PORT QD Monday through Friday over 15-25 fractions over 5-6 weeks. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.

Interventions

  • Procedure Biospecimen Collection

    Undergo blood sample collection

  • Drug Chemotherapy

    Receive standard of care chemotherapy

  • Procedure Computed Tomography

    Undergo CT

  • Other Fludeoxyglucose F-18

    Undergo FDG PET scan

  • Other Immunotherapy

    Receive standard of care immunotherapy

  • Radiation Intensity-Modulated Radiation Therapy

    Undergo I²-PORT

  • Procedure Magnetic Resonance Imaging

    Undergo MRI

Outcome measures

  1. Primary outcome

    Disease-free survival (DFS)

    DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. The median DFS for each treatment group will be estimated, and its 80% and 90% confidence intervals will be calculated using the Kaplan-Meier estimator. Additionally, the 24-month DFS rate for each treatment arm, along with its confidence intervals, will be calculated.

    Time frame Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years

  2. Primary outcome

    Incidence of late grade ≥ 3 cardiopulmonary toxicities

    Will be assessed according to the Common Terminology Criteria for Adverse Events version 5.0. Will be estimated for each treatment group and the difference between the two treatment groups. The confidence intervals of the rate difference at 80% and 90% significance levels will be estimated using the Miettinen-Nurminen method.

    Time frame Between 3 and 24 months after protocol therapy

  3. Secondary outcome

    5-year DFS

    DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1

    Time frame Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years

  4. Secondary outcome

    2-year overall survival (OS)

    Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.

    Time frame Time from the date of randomization to death from all causes, assessed up to 2 years

  5. Secondary outcome

    5-year OS

    Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.

    Time frame Time from the date of randomization to death from all causes, assessed up to 5 years Symptomatic skeletal event free survival (SSE-FS)

  6. Secondary outcome

    Patient-reported symptoms

    Will be assessed using Patient Reported Outcomes - Common Terminology Criteria for Adverse Events and will be evaluated for between-arm differences in proportions of patients with a maximum post-baseline score greater than 0 using Fisher's exact or chi-square test.

    Time frame up to 5 years

Dates

Dates
Start dateOctober 14, 2026 (estimated)
Primary completionDecember 31, 2032 (estimated)
CompletionMarch 1, 2036 (estimated)
First postedDecember 19, 2025 (actual)
Last updatedNovember 3, 2026
Results postedNot stated in the registry record
Status last verifiedNovember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

121 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn ArborMichiganRecruiting
Northwest Wisconsin Cancer CenterAshlandWisconsinRecruiting
Duluth Clinic AshlandAshlandWisconsinRecruiting
Mount Sinai Comprehensive Cancer Center at AventuraAventuraFloridaRecruiting
Memorial Sloan Kettering Basking RidgeBasking RidgeNew JerseyRecruiting
MaineHealth Coastal Cancer Treatment CenterBathMaineRecruiting
UPMC-Heritage Valley Health System BeaverBeaverPennsylvaniaRecruiting
Sanford Joe Lueken Cancer CenterBemidjiMinnesotaRecruiting
Sanford Bismarck Medical CenterBismarckNorth DakotaRecruiting
Illinois CancerCare-BloomingtonBloomingtonIllinoisRecruiting
OSF Saint Joseph Medical CenterBloomingtonIllinoisRecruiting
Essentia Health Saint Joseph's Medical CenterBrainerdMinnesotaRecruiting
Trinity Health IHA Medical Group Hematology Oncology - BrightonBrightonMichiganRecruiting
Trinity Health Medical Center - BrightonBrightonMichiganRecruiting
MaineHealth Cancer Care and IV Therapy - BrunswickBrunswickMaineRecruiting
Trinity Health Medical Center - CantonCantonMichiganRecruiting
Trinity Health IHA Medical Group Hematology Oncology - CantonCantonMichiganRecruiting
Illinois CancerCare-CantonCantonIllinoisRecruiting
Saint Francis Medical CenterCape GirardeauMissouriRecruiting
Carlisle Regional Cancer CenterCarlislePennsylvaniaRecruiting
Illinois CancerCare-CarthageCarthageIllinoisRecruiting
UNC Lineberger Comprehensive Cancer CenterChapel HillNorth CarolinaRecruiting
Medical University of South CarolinaCharlestonSouth CarolinaRecruiting
Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelseaMichiganRecruiting
Chelsea HospitalChelseaMichiganRecruiting
Rush MD Anderson Cancer CenterChicagoIllinoisRecruiting
Clackamas Radiation Oncology CenterClackamasOregonRecruiting
Baptist Memorial Hospital and Cancer Center-ColliervilleColliervilleTennesseeRecruiting
Ohio State University Comprehensive Cancer CenterColumbusOhioRecruiting
Memorial Sloan Kettering CommackCommackNew YorkRecruiting
Cancer Care Specialists of Illinois - DecaturDecaturIllinoisRecruiting
Decatur Memorial HospitalDecaturIllinoisRecruiting
Essentia Health - Deer River ClinicDeer RiverMinnesotaRecruiting
Essentia Health Cancer CenterDuluthMinnesotaRecruiting
Miller-Dwan HospitalDuluthMinnesotaRecruiting
Essentia Health Saint Mary's Medical CenterDuluthMinnesotaRecruiting
Duke University Medical CenterDurhamNorth CarolinaRecruiting
Marshfield Medical Center-EC Cancer CenterEau ClaireWisconsinRecruiting
UPMC Hillman Cancer Center ErieEriePennsylvaniaRecruiting
Illinois CancerCare-EurekaEurekaIllinoisRecruiting
Sanford Roger Maris Cancer CenterFargoNorth DakotaRecruiting
Sanford Broadway Medical CenterFargoNorth DakotaRecruiting
Parkland Health Center - FarmingtonFarmingtonMissouriSuspended
UPMC Cancer Center at UPMC HorizonFarrellPennsylvaniaRecruiting
Illinois CancerCare-GalesburgGalesburgIllinoisRecruiting
UPMC Cancer Centers - Arnold Palmer PavilionGreensburgPennsylvaniaRecruiting
UPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburgPennsylvaniaRecruiting
Memorial Sloan Kettering WestchesterHarrisonNew YorkRecruiting
Essentia Health-Hayward ClinicHaywardWisconsinRecruiting
Essentia Health Hibbing ClinicHibbingMinnesotaRecruiting

75 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. November 3, 2026

    Site added

    14 sites added (125 total)

    111125

  2. October 19, 2026

    Completion date moved later

    Primary completion delayed 1461 days

    2028-12-312032-12-31

  3. October 2, 2026

    Site added

    14 sites added (111 total)

    97111

  4. September 2, 2026

    Site added

    23 sites added (97 total)

    7497

  5. August 5, 2026

    Site added

    41 sites added (74 total)

    3374